Treats moderate to severe plaque psoriasis of the scalp and mild to moderate plaque…. ANDA 210809, held by Glenmark Pharms Ltd. Clobetasol Propionate.
As of Nov 16, 2026, ANDA 210809 (Clobetasol Propionate), held by Glenmark Pharms Ltd, was first approved by FDA on Feb 15, 2019, with 3 approved supplements and 0 published complete response letters.
Clobetasol propionate foam is a corticosteroid indicated for treatment of moderate to severe plaque psoriasis of the scalp and mild to moderate plaque psoriasis of non-scalp regions of the body excluding the face and intertriginous areas in patients 12 years and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 15, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Clobetasol Propionate0.05% · aerosol, foam;topical | Clobetasol Propionate | Rx |
| Nov 29, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 29, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 29, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 15, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters